SCHEMBL2401211

SCHEMBL2401211

CC=C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OO[Si](C)(C)CCCC)ccc4[C@H]3CC[C@@]21C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.53
ESR2 Q92731 2/20 0.53
STS P08842 10/20 0.50
NR3C1 P04150 4/20 0.49
NR3C2 P08235 1/20 0.48
LMNA P02545 3/20 0.48
PGR P06401 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
HIF1A Q16665 1/20 0.48
CNR1 P21554 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8638232 0.83 STS (0.51) ESR1ESR2STSNR3C1NR3C2
SCHEMBL8145976 0.79 ESR1 (0.55) ESR1ESR2STSNR3C1NR3C2
SCHEMBL8145253 0.79 ESR1 (0.55) ESR1ESR2STSNR3C1NR3C2
SCHEMBL2399541 0.78 HSD17B1 (0.66) ESR1ESR2STSLMNAPGR
SCHEMBL22181611 0.78 STS (0.71) ESR1ESR2STSNR3C1NR3C2
SCHEMBL9603296 0.78 ESR1 (0.56) ESR1ESR2STSNR3C1NR3C2
SCHEMBL10631994 0.77 ESR1 (0.63) ESR1ESR2STSNR3C1LMNA
SCHEMBL10599506 0.77 ESR1 (0.63) ESR1ESR2STSNR3C1LMNA
SCHEMBL5983440 0.75 ESR1 (0.56) ESR1ESR2STSNR3C1NR3C2
SCHEMBL2677733 0.75 ESR1 (0.56) ESR1ESR2STSNR3C1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111409-B1 NOVEL CATIONIC 17 ALPHA- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT COUNCIL SCIENT IND RES (IN) 2012-06-27 EP disclosed
US-8012952-B2 Cationic 17 α-substituted-estradiol derivatives useful as anti-cancer agent COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-09-06 US disclosed
EP-2111409-A1 NOVEL CATIONIC 17 ALPHA- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT Council of Scientific&Industrial Research (IN) 2009-10-28 EP disclosed
US-20090062230-A1 NOVEL CATIONIC 17 ALPHA-SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-03-05 US disclosed
WO-2008099414-A1 NOVEL CATIONIC 17 α- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062230-A1 NOVEL CATIONIC 17 ALPHA-SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT ESR2, ESR1, GPER1 ESR1 2/4885ESR2 1/4885STS 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.